Molecular Endocrinology, Vol 6, 2167-2174, Copyright © 1992 by Endocrine Society

ARTICLES

Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER

SY Jiang, SM Langan-Fahey, AL Stella, R McCague and VC Jordan
Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792.

The antiestrogen tamoxifen is used in the treatment of hormone- responsive breast cancer. However, therapeutic failure has frequently been observed in both patients and animal models after long term treatment. We have studied the effect of a point mutation that leads to the substitution of Val for Gly at codon 400 in the ligand-binding domain of the estrogen receptor (ER) on estrogenic and antiestrogenic activities of 4-hydroxytamoxifen (4-OHT) and its derivatives. Stable ER transfectants derived from MDA-MB-231 CL10A, an ER-negative breast cancer cell line, have been used in these studies. 4-OHT and its fixed ring derivatives showed more estrogen-like activity in ER transfectants than in MCF-7, an ER-positive breast cancer cell line. In this study, 4- OHT was a partial agonist of cell growth in the transfectant S30 cells, which express the wild-type ER. However, it was a full agonist in the mutant ER transfectant ML alpha 2H, which expressed ER with Val at codon 400. The increased estrogenic activity of 4-OHT in ML alpha 2H cells was not due to the preferential isomerization of trans 4-OHT to cis 4-OHT, since the nonisomerizable fixed ring trans 4-OHT was a partial agonist for cell growth in S30 cells and was a full agonist in ML alpha 2H cells. Transient transfection using a reporter plasmid containing an estrogen response element demonstrated that fixed ring trans 4-OHT had estrogenic activity in ML alpha 2H cells.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				M. H. Herynk and S. A. W. Fuqua Estrogen Receptor Mutations in Human Disease Endocr. Rev., December 1, 2004; 25(6): 869 - 898. [Abstract] [Full Text] [PDF]

				V. S. Wilson, K. Bobseine, C. R. Lambright, and L. E. Gray Jr. A Novel Cell Line, MDA-kb2, That Stably Expresses an Androgen- and Glucocorticoid-Responsive Reporter for the Detection of Hormone Receptor Agonists and Antagonists Toxicol. Sci., March 1, 2002; 66(1): 69 - 81. [Abstract] [Full Text] [PDF]

				K. P. L. Bhat, D. Lantvit, K. Christov, R. G. Mehta, R. C. Moon, and J. M. Pezzuto Estrogenic and Antiestrogenic Properties of Resveratrol in Mammary Tumor Models Cancer Res., October 1, 2001; 61(20): 7456 - 7463. [Abstract] [Full Text] [PDF]

				H. Liu, E.-S. Lee, A. D. L. Reyes, J. W. Zapf, and V. C. Jordan Silencing and Reactivation of the Selective Estrogen Receptor Modulator-Estrogen Receptor {{alpha}} Complex Cancer Res., May 1, 2001; 61(9): 3632 - 3639. [Abstract] [Full Text]

				R. Clarke, F. Leonessa, J. N. Welch, and T. C. Skaar Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance Pharmacol. Rev., March 1, 2001; 53(1): 25 - 72. [Abstract] [Full Text] [PDF]

				H.-L. C. Liu, E. Golder-Novoselsky, M. H. Seto, L. Webster, J. McClary, and D. A. Zajchowski The Novel Estrogen-Responsive B Box Protein (EBBP) Gene Is Tamoxifen Regulated in Cells Expressing an Estrogen Receptor DNA-Binding Domain Mutant Mol. Endocrinol., November 1, 1998; 12(11): 1733 - 1748. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				C.-i. Wong, W. R. Kelce, M. Sar, and E. M. Wilson Androgen Receptor Antagonist versus Agonist Activities of the Fungicide Vinclozolin Relative to Hydroxyflutamide J. Biol. Chem., August 25, 1995; 270(34): 19998 - 20003. [Abstract] [Full Text] [PDF]

				M. Morrow and V. C. Jordan Molecular Mechanisms of Resistance to Tamoxifen Therapy in Breast Cancer Arch Surg, November 1, 1993; 128(11): 1187 - 1191. [Abstract] [PDF]